Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

BACKGROUND: This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD) or twice daily (BID) in combination with erl...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2011
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3161034/
https://ncbi.nlm.nih.gov/pubmed/21791058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-313
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares